What To Know
- The company notes as part of the collaboration, NYU Grossman School of Medicine neurosurgery residents and research fellows will have the opportunity to work with the Proprio technology development team at Proprio’s Seattle headquarters, contributing to product requirements, testing versions of the Proprio system, providing surgical guidance on product development, and conducting clinical studies.
- Working with their Department of Neurosurgery will help us bring to market an imaging and navigation system that lets surgeons focus on the patient in an entirely new way.
January 21, 2021
Proprio notes that Dr. John Golfinos, the Joseph P. Ransohoff Professor and Chair of the Department of Neurosurgery, will serve as the Project Director.
Dr. Golfinos will help guide research and the development of the company’s breakthrough imaging and navigation system for neurosurgical and spinal applications.
“Proprio is pleased to have one of the nation’s leading academic neurosurgery programs as a research collaborator,” said Gabriel Jones, Co-Founder and CEO of Proprio. “We believe leading programs like NYU Grossman School of Medicine can play a key role in the design of surgeon-centric products. Working with their Department of Neurosurgery will help us bring to market an imaging and navigation system that lets surgeons focus on the patient in an entirely new way.”
“Our department has long been a leader in advancing patient care through revolutionary technology and world-class surgical technique,” said Dr. Golfinos. “We’re excited about the Proprio system’s potential to greatly improve the accuracy and efficiency of complex surgeries.”
The company notes as part of the collaboration, NYU Grossman School of Medicine neurosurgery residents and research fellows will have the opportunity to work with the Proprio technology development team at Proprio’s Seattle headquarters, contributing to product requirements, testing versions of the Proprio system, providing surgical guidance on product development, and conducting clinical studies. Proprio intends to place units at NYU for in situ studies upon receiving FDA clearance.
